Informe Conjunto de Organizaciones de Defensa del Derecho a la Salud al Comité de Derechos Económicos y Sociales de las Naciones Unidas, con motivo del Examen del 3er Informe Periódico del Estado Venezolano en el Período de Sesión 55° del Pacto Internacional de Derechos Económicos, Sociales y... Culturales
more
Поэтому уже давно возникала мысль о том,что подробный комментарий по вопросам научных знаний и практическогоопыта, лежащих в основе политики ВОЗ по борьбе ...с туберкулезом, являлся бысущественным элементом технического сотрудничества ВОЗ с ее государствамичленами. Данная книга, написанная в форме вопросов и ответов, являетсяпервым шагом в этом направлении. Я надеюсь, что она станет доступной длявсех специалистов, участвующих в борьбе с туберкулезом, организаторов здравоохранения и администраторов, ответственных за формирование и выполнение национальных программ борьбы с туберкулезом, а также всех медицинскихработников, ежедневно решающих конкретные задачи борьбы с туберкулезомна местах.
more
Guidelines for Therapy and Management of Pediatric Urology in Indonesia
Prepared as an outcome of ICMR Expert Group on Immunophenotyping of Hematolymphoid Neoplasms | Coordinated by Division of Non Communicable Diseases | This document addresses on various issue related to good quality practices in laboratory work up of flow cytometric immunophenotyping and will be of u...se to pathologists, cytometrists, hematologists, technologists and scientists working in this field.
more
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
Conducted November 2011 to February 2012: Summary Report
This summary report has five sections. Following the introduction (Section 1), Section 2 sets out summary findings and recommendations of the assessment team. Section 3 describes the context in which artemisinin resistance is being tackle...d. Section 4 highlights key achievements and enabling factors for the response to artemisinin resistance, whilst Section 5 provides a more detailed discussion of major issues to be addressed.
more
Technical report
This manual aims to provide information about the methods for investigating outbreaks of hepatitis E, and measures for their prevention and control. In addition, the manual gives information about the causative agent – known as the hepatitis E virus (HEV) – its epidemiology..., clinical manifestations of the disease and diagnosis.
more
WHO TRS N°1012.
Key updates include: (i) surveillance strategies, including cross-sectoral linking of systems and suitable diagnostics; (ii) the latest recommendations on human and animal immunization; (iii) palliative care in lowresource settings; (iv) risk assessment to guide management of bite... victims; and (v) a proposed process for validation and verification of countries reaching zero human deaths from rabies.
more
Октябрь 2017
Русский
Рекомендации EACS 9.0
This module is part of the WHO series The Immunological Basis for Immunization, which was initially developed in 1993 as a set of eight modules, comprising one module on general immunology and seven modules each devoted to one of the vaccines recommended for the Expanded Programme on Immunization, i....e. vaccines against diphtheria, measles, pertussis, polio, tetanus, tuberculosis and yellow fever. Since then, this series has been updated and extended to include other vaccines of international importance. The main purpose of the modules is to provide national immunization managers and vaccination professionals with an overview of the scientific basis of vaccination against a range of important infectious diseases. The modules developed since 1993 continue to be vaccine-specific, reflecting the biological differences in immune responses to the individual pathogens and the differing strategies employed to create the best possible level of protection that can be provided by vaccination. The modules also serve as a record of the immunological basis for the WHO recommendations on vaccine use, published in the WHO vaccine position papers.*
more
February 2021.
Improving our response to the ongoing COVID-19 pandemic in Africa requires regularly updated information, constant innovation, and considerable support towards research and development (R&D) for priorities that respond to the African realities. Shaping the research agenda and stimula...ting the generation, translation, and dissemination of valuable knowledge is one of the core functions of the African Academy of Sciences (AAS), African Centre for Disease Control (Africa CDC), and WHO-AFRO. We need answers to a list of critical research questions that respond to the current realities on the African continent to guide the COVID-19 outbreak control efforts
more
29 Dec 2021. Comprehensive slideset updated regularly to include the latest data and guidance on best practices for COVID-19 diagnosis and prevention of COVID-19 transmission.
Health ministries currently lack effective tools for monitoring and evaluation of schistosomiasis control programmes. Egg detection can be used, but the cost, challenges of obtaining samples, and the need for trained personnel and equipment limit the frequency of monitoring. The purpose of this TPP ...is to guide the development of new diagnostic tools to reliably measure when prevalence is above or below a cut-off of 10% in school-aged children. Communities remaining above 10% require annual MDA, while communities below 10% can reduce MDA frequency as long as < 10% prevalence can be maintained. However, the lack of a reliable test has hindered the development of maintenance strategies. The test is also needed to track changes of prevalence > 10% to ensure that annual MDA is reducing overall prevalence.
more
La néphrologie pédiatrique (NP) a connu ces dernières années des progrès impressionnants en matière de soins. Cependant, le plus grand défi dans notre continent africain est de fournir aux enfants atteints de maladie rénale l’accès à une prise en
charge spécialisée par des néphrologu...es pédiatriques ayant une bonne formation, ainsi que la possibilité d’avoir un accès abordable aux techniques modernes, aux médicaments efficaces et à des stratégies de prévention. En Afrique, le développement de la NP a été très lent et sans collaboration réelle entre les pays concernés, ce qui a renforcé ma conviction sur la nécessité d’amener les néphrologues pédiatres africains à œuvrer ensemble, par le biais d’un ouvrage commun, à mettre en lumière les données spécifiques de notre continent dans ce domaine.
more
Revised and expanded version of the Guidelines